Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.

J Eur Acad Dermatol Venereol

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Published: November 2021

Download full-text PDF	Source
http://dx.doi.org/10.1111/jdv.17427	DOI Listing

Publication Analysis

low incidence

incidence rate

rate respiratory

respiratory viral

viral infections

infections years

years treatment

treatment tildrakizumab

tildrakizumab patients

patients moderate-to-severe

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!